RxDoctor Payments Data

Jeremy Korteweg, MD

Family Medicine · Waco, TXNPI 1073801015

Payments from drug & device makers

$4,040in general payments, 2019–2025

Across 209 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$564
  • Lilly USA, LLC$382
  • Pfizer$296
  • Amgen$278
  • Dexcom, Inc.$214
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$4,040100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,040 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$6,776
Medicare patients
43
Services billed
343

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin108$151,187
OzempicSemaglutide111$138,097
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$57,250
LinzessLinaclotide49$35,627
TrulicityDulaglutide19$35,156
DescovyEmtricitabine/Tenofov Alafenam13$28,726
TradjentaLinagliptin23$28,642
EliquisApixaban27$26,008
MounjaroTirzepatide13$20,241
EntrestoSacubitril/Valsartan27$17,194
Tresiba Flextouch U-200Insulin Degludec15$16,903
JanuviaSitagliptin Phosphate14$15,175
MyrbetriqMirabegron21$14,927
Breo ElliptaFluticasone/Vilanterol12$9,984
Incruse ElliptaUmeclidinium Bromide11$6,744

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$87$179,828131 claims
Novo NordiskOzempic$564$138,097111 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$134$73,97890 claims
Lilly USA, LLCTrulicity, Mounjaro$382$55,39732 claims
AbbVieLinzess$1,064$35,62749 claims
PfizerEliquis$296$26,00827 claims
NovartisEntresto$92$17,19427 claims
MerckJanuvia$57$15,17514 claims
AstraZenecaSymbicort$14$2,57711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Waco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →